Pfizer Celecoxib has met its primary endpoint in a Phase IV trial evaluating its effects on blood pressure in paediatric patients with juvenile idiopathic arthritis (JIA).
No virtual difference in the primary and secondary endpoints, systolic blood pressure and diastolic blood pressure, between the celecoxib and naproxen treatment groups were noted.
Go deeper with GlobalData
A similar safety profile was observed in both the groups. Headache, nausea and joint aches were the most common adverse events reported in both treatment groups.
The double-blind, multicentre study was conducted for six weeks to evaluate 50mg or 100mg Celecoxib twice a day or 7.5mg/kg naproxen twice a day.
A total of 201 patients from 10 different countries diagnosed with JIA, including patients with oligoarticular JIA (where few joints are affected) and polyarticular JIA (where many joints are affected), participated in the study.
See Also:
The company carried out the study as part of a post-marketing commitment to the US Food and Drug Administration for Celebrex.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataImage: Pfizer celebrex has been approved by the FDA for the relief of the signs and symptoms of JRA in pediatric patients two years of age and older. Photo: Courtesy of Jim Henderson.
